Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile
Paolo A. Ascierto, Anna Maria Di Giacomo, Vanna Chiarion‐Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandalà, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier Francesco Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Di Maïo, Pietro Quaglino, Michele Del Vecchio
Topics & Concepts
NivolumabMedicineIpilimumabInternal medicineAdverse effectPopulationMelanomaStage (stratigraphy)AdjuvantOncologyExpanded accessCohortCancerSurgeryImmunotherapyCancer researchPaleontologyEnvironmental healthBiologyCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways